Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation
- PMID: 22790906
- DOI: 10.1007/s10620-012-2306-1
Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation
Abstract
Background: The present study evaluated performance characteristics of liver stiffness measurement (LSM) by FibroScan in patients with different stages of nonalcoholic fatty liver disease (NAFLD).
Patients and methods: A total of 307 subjects (120 NAFLD, 85 NAFLD related cirrhosis, and 102 healthy controls) were studied.
Results: In NAFLD patients, LSM had significant correlation with fibrosis (r = 0.68, p < 0.001), and increased progressively with increasing fibrosis (p < 0.001). However, the difference between stage 1 and stage 2 fibrosis was not significant (p = 0.07). The LSM in NAFLD without fibrosis and healthy controls was similar (p = 0.37). The areas under receiver-operating characteristics (AUROC) curve of LSM for stages ≥1, ≥2, ≥3, and 4 were 0.82, 0.85, 0.94, and 0.96, respectively. The best LSM (kPa) cut-offs for fibrosis stages ≥1, ≥2, ≥3 and 4 were 6.1, 7.0, 9.0, and 11.8, respectively. The negative predictive value of LSM for excluding advanced fibrosis was 95%. For advanced fibrosis, the AUROC curve of LSM was 0.94, followed by FIB-4 (0.75), BARD score (0.68), NAFLD fibrosis score (0.66), and aspartate platelet ratio index (0.60). In multivariate analysis, LSM was the only independent predictor of advanced fibrosis (odds ratio 1.47). In patients with NAFLD cirrhosis, LSM correlated significantly with Child-Pugh score (r = 0.40, p < 0.001), serum bilirubin (r = 0.34, p = 0.02), and grades of esophageal varices (r = 0.23, p = 0.04).
Conclusion: LSM is a useful tool for evaluation of patients with NAFLD, and is the best among other non-invasive predictors of liver fibrosis.
Similar articles
-
Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.Clin Gastroenterol Hepatol. 2019 Jan;17(1):156-163.e2. doi: 10.1016/j.cgh.2018.04.043. Epub 2018 Apr 26. Clin Gastroenterol Hepatol. 2019. PMID: 29705261 Free PMC article.
-
[Diagnostic value of liver stiffness measurement for the evaluation of liver fibrosis in nonalcoholic fatty liver].Zhonghua Gan Zang Bing Za Zhi. 2020 Jul 20;28(7):567-572. doi: 10.3760/cma.j.cn501113-20190302-00065. Zhonghua Gan Zang Bing Za Zhi. 2020. PMID: 32791791 Chinese.
-
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD.Clin Gastroenterol Hepatol. 2023 May;21(5):1293-1302.e5. doi: 10.1016/j.cgh.2022.06.013. Epub 2022 Jul 14. Clin Gastroenterol Hepatol. 2023. PMID: 35842119
-
Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.Hepatology. 2017 Nov;66(5):1486-1501. doi: 10.1002/hep.29302. Epub 2017 Sep 26. Hepatology. 2017. PMID: 28586172 Review.
-
Liver stiffness is associated with all-cause mortality in patients with NAFLD: A systematic review and meta-analysis.Liver Int. 2023 Dec;43(12):2604-2610. doi: 10.1111/liv.15742. Epub 2023 Sep 19. Liver Int. 2023. PMID: 37724792 Review.
Cited by
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.Front Nutr. 2024 Feb 14;11:1284509. doi: 10.3389/fnut.2024.1284509. eCollection 2024. Front Nutr. 2024. PMID: 38419854 Free PMC article.
-
Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease.Int J Clin Exp Med. 2014 Nov 15;7(11):4191-8. eCollection 2014. Int J Clin Exp Med. 2014. PMID: 25550930 Free PMC article.
-
Non-Invasive Diagnostic of NAFLD in Type 2 Diabetes Mellitus and Risk Stratification: Strengths and Limitations.Life (Basel). 2023 Nov 27;13(12):2262. doi: 10.3390/life13122262. Life (Basel). 2023. PMID: 38137863 Free PMC article. Review.
-
Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic.Biomedicines. 2021 Dec 9;9(12):1866. doi: 10.3390/biomedicines9121866. Biomedicines. 2021. PMID: 34944682 Free PMC article. Review.
-
Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.EClinicalMedicine. 2022 Jul 10;51:101547. doi: 10.1016/j.eclinm.2022.101547. eCollection 2022 Sep. EClinicalMedicine. 2022. PMID: 35844772 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical